United States Endometriosis Treatment Market Size, Share, and Growth Forecast 2025-2033: From US$1.59 Billion in 2024 to US$3.91 Billion at 10.62% CAGR, Driven by Hormone Therapies, New Oral Approvals like Relugolix, and Non-Hormonal Innovations

The Global Endometriosis Treatment market reached US$ 1.59 billion in 2024 and is expected to reach US$ 3.91 billion by 2033, growing at a CAGR of 10.62% during the forecast period 2025-2033.

According to DataM Intelligence has published a new research report on "Endometriosis Treatment Market Size 2025". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status.

📌 Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/endometriosis-treatment-market?rk

➣ Regulatory & Therapy Advances
✅ In March 2025, the UK approved relugolix-estradiol-norethisterone as the first long-term daily oral pill for endometriosis. The therapy offers a convenient at-home option compared to injections or surgical approaches.
✅ In May 2025, another oral therapy, linzagolix with add-back hormones, was cleared for women whose previous treatments were ineffective. Clinical studies showed improvements in painful periods and chronic pelvic pain.
✅ These new approvals are expected to expand access, improve treatment adherence, and shift the standard of care toward more patient-friendly, minimally invasive therapies.

➣ Research & Innovation Toward Non-Hormonal Treatments
✅ Researchers have recently identified new immune-cell communication pathways involved in endometriosis lesions. These findings open the door to potential non-hormonal drugs that could reduce inflammation and pain without suppressing natural hormonal cycles.
✅ Experimental metabolic-targeting compounds, including agents that restore mitochondrial function in endometrial cells, are demonstrating early promise in reducing lesion growth and inflammation.

➣ Advances in Diagnosis & Clinical Practice
✅ Multiple countries are updating clinical guidelines to reduce the common 7-10 year diagnostic delay. New management plans aim to improve early detection and streamline care pathways at general-practice levels.
✅ AI-powered imaging tools and enhanced diagnostic platforms are being piloted to better identify lesions, assess severity, and reduce reliance on invasive laparoscopic procedures.

➣ Top Industry Players:

Bayer AG, Pfizer, Inc., AbbVie, Inc, AstraZeneca, Gedeon Richter Plc., TORRENT PHARMACEUTICALS LTD., Sanofi SA, Gynogen, and Weefsel Pharma.

📌 Buy Now & Get 30% OFF - (Grab 50% OFF on 2+ reports) @: https://www.datamintelligence.com/buy-now-page?report=endometriosis-treatment-market?rk

➣ Key Segments:

By Treatment Type: Pain Medication, Hormone Therapy

By Drug Class: NSAIDs, Oral Contraceptives, Gonadotropin-Releasing Hormone, Others

By Route of Administration: Oral, Injectable, Others

By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, e-Commerce, Others

📌 Get Customization in the report as per your requirements: https://datamintelligence.com/customize/endometriosis-treatment-market?rk

➣ Product Launches:

1. Pharmaceuticals
• AbbVie - Updated Orilissa (Elagolix) Dosing Programs (2024)
Enhanced dosing programs and patient-support tools were launched in the U.S. to expand access for moderate-to-severe endometriosis pain.

• Myovant Sciences & Pfizer - Myfembree Expansion (2024)
After U.S. approval, the companies expanded Myfembree (relugolix combination therapy) into new regions and introduced a new blister-pack format to improve compliance.

• ObsEva - Nolasiban-based Innovations (2024-2025)
Released new data and updated formulations in Europe focused on reproductive health-including patients with endometriosis undergoing fertility treatment.

2. Medical Devices & Minimally Invasive Technologies
• Intuitive Surgical - Da Vinci Xi Upgrades (2024)
New robotic instruments for precision excision of deep infiltrating endometriosis (DIE).

• Olympus - VISERA Elite III (2024)
A next-generation imaging platform launched for high-contrast endometriosis lesion identification during laparoscopy.

• Hologic - NovaSure Advance (2023-2024 Updates)
Improved energy-delivery features for use in abnormal bleeding management, often needed in endometriosis-associated heavy menstrual bleeding.

3. Diagnostics & Biomarkers
• DotLab - DotEndo Test (2024 Commercial Expansion)
A first-of-its-kind noninvasive blood-based microRNA test for early detection of endometriosis launched commercially in the U.S.

• Roche Diagnostics - High-Sensitivity Endometriosis Biomarker Panel (2024)
Introduced improved hormonal and inflammatory marker panels for early diagnosis.

4. Digital Health / AI-Based Tools
• Flo Health - Endometriosis Symptom AI Module (2024)
Personalized symptom-tracking and AI-based flare prediction for patients.

• Natural Cycles - Endo-Awareness Updates (2024)
New insights module to help identify patterns consistent with chronic pelvic pain & endometriosis risk.

• HeraMED - Digital Pelvic Pain Monitoring (2023-2024)
Launched remote monitoring tools integrated with gynecology clinics.

📌 Have any Enquiry of This Report @ https://www.datamintelligence.com/enquiry/endometriosis-treatment-market?rk

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

☛ Get 2-Day Free Trial + 50% OFF DataM Subscription@ https://www.datamintelligence.com/reports-subscription?rk

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.